Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, FCO2 laser treatment showed significantly better improvement for alopecia areata compared to traditional intralesional corticosteroid injections, with no serious side effects or relapse observed.

This case report describes a 62-year-old male with multiple warty dyskeratomas found on the scalp, chest, abdomen, and lower back, a rare presentation confirmed by histological findings consistent with warty dyskeratoma, as noted by the researchers.

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

In this case report, a 2-year-old girl with severe alopecia areata experienced significant hair regrowth after 37 weeks of treatment with dupilumab and minoxidil, but the combination of treatments and possible spontaneous recovery mean the improvement cannot be solely credited to dupilumab.

In this study, patients with Alopecia Areata showed significant clinical improvement after intralesional steroid treatment, as trichoscopic features like black dots and exclamation mark hairs decreased, while short vellus and circle hairs increased, highlighting Trichoscopy's utility in monitoring treatment response.

In this study, platelet-rich plasma therapy was observed to provide better improvement in hair regrowth for alopecia areata patients than intralesional triamcinolone acetonide, as measured by lower SALT scores.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

This study found that while patients with alopecia areata in Europe experienced substantial reductions in hair loss severity, only a few achieved and sustained a significant improvement in their condition.

This study found that scalp micropigmentation was a safe and effective cosmetic solution for localized alopecia, showing significant improvement in visual density and high patient satisfaction without adverse events.

This study found that baricitinib significantly reduced hair loss in patients with severe alopecia areata, decreasing the mean SALT score from 96.6 to 48 over 24 weeks, with no patients dropping out and only mild adverse events in 12.7% of participants.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

In this study, researchers found that among patients with severe alopecia areata, a change in SALT scores of 42 or 43 points represents meaningful improvement, highlighting the need to consider individual treatment goals beyond conventional low SALT score targets when assessing treatment benefits.

In this study, adding intralesional platelet rich plasma to topical mometasone proved more effective and showed earlier improvement in treating alopecia areata compared to using topical mometasone alone.

This study found that among patients with twenty-nail dystrophy, those treated with oral cyclosporine in combination with a dietary supplement showed significantly better improvement in nail condition and quality of life than those treated with the supplement alone.

In this study, patients with severe alopecia areata who were treated with baricitinib 4 mg/day for 48 weeks showed significant improvements in both hair regrowth and nail abnormalities, although the correlation between hair and nail improvement was weak.

In this study, intralesional pentoxifylline was found to be an effective and well-tolerated treatment for alopecia areata, showing significant improvements in hair loss with minimal side effects and a low recurrence rate among the 50 patients tested over 12 weeks.

This study found that although patients with significant scalp hair loss experienced substantial reductions in Severity of Alopecia Tool scores, few maintained this improvement over time, indicating potential suboptimal effectiveness of current treatments.

This study found that among placebo-treated patients in the BRAVE-AA trials, the likelihood of spontaneous hair regrowth in untreated severe alopecia areata was low, with only a small percentage achieving significant scalp, eyebrow, or eyelash hair improvement over 36 weeks.

This study found that human placental extract significantly improved melasma, chronic ulcers, and alopecia areata without major adverse effects, suggesting its effectiveness and safety for these conditions.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.

This study found that topical calcipotriol may safely and effectively treat mild-to-moderate patchy alopecia areata, with significant hair regrowth observed in the majority of participants over 12 weeks.

This study found that treatment with fractional 1064 nm picosecond Nd:YAG laser effectively reduced post-acne erythema in adult Chinese patients without causing scarring or pigmentation issues, though some experienced temporary erythema, oedema, pruritus, and acne eruptions.

In this study of 36 women with chronic telogen effluvium, once daily oral minoxidil significantly reduced hair shedding over 12 months, though some participants experienced facial hypertrichosis and other mild side effects. The authors concluded that placebo-controlled studies are needed to confirm these results.

This pilot study found that an 8-week treatment with a hyaluronic acid and hydrogen peroxide gel improved folliculitis symptoms and patient satisfaction, supporting its potential use in dermatologic practice and future trials.

Oral minoxidil effectively reduces hair shedding in women with chronic telogen effluvium.

This study found that platelet-rich plasma injections improved alopecia severity scores in women with androgenetic alopecia after six months, though further research is needed to confirm these results.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This study found that Plinest injections improved skin hydration and elasticity in the face, neck, and décolleté and were well-tolerated, with high patient satisfaction over a 4-month follow-up.

This study concluded that oral tofacitinib significantly improved hair growth in patients with alopecia areata, alopecia totalis, and alopecia universalis over a 24-week period, but longer studies are needed to assess long-term safety.

This study found that in women with PCOS, suppressive therapy using spironolactone plus oral contraceptives improved hirsutism more effectively than either treatment alone, with initial scores predicting success.